Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose 5% provides a source of calories and fluid for hydration, preventing ketosis by providing a minimal carbohydrate source. Sodium chloride 0.9% supplies electrolytes and maintains osmotic pressure in extracellular fluid.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Fluid and electrolyte replacement in patients with isotonic dehydration,Maintenance of hydration and electrolyte balance when oral intake is inadequate,Vehicle for intravenous administration of compatible drugs,Hypovolemia (off-label),Shock (off-label)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion; typical adult dose is 500-1000 m L as a single dose, administered at a rate determined by clinical condition (e.g., 100-200 m L/h for maintenance).
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Glucose has a plasma half-life of approximately 1.5-2.5 hours in normal individuals, reflecting rapid cellular uptake and metabolism. Sodium and chloride have no definable half-life as they are actively regulated; however, the half-life of infused sodium is approximately 2-4 hours depending on renal function.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Dextrose is metabolized via glycolysis and the Krebs cycle to carbon dioxide and water; insulin-dependent. Sodium chloride is not metabolized; excreted renally.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Glucose is completely metabolized to CO2 and water; renal excretion of unchanged glucose is negligible (<1%) in normoglycemic patients. Sodium and chloride are primarily excreted renally (90-95% of infused load) with small fecal and sweat losses. In dextrose 5% and sodium chloride 0.9%, both components are eliminated renally; the dextrose is metabolized, not excreted unchanged.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Dextrose: negligible (<1%) binding to plasma proteins. Sodium: not protein-bound. Chloride: not protein-bound.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Dextrose: Vd approximately 0.15-0.25 L/kg (primarily extracellular fluid). Sodium and chloride: Vd approximately 0.25 L/kg (distributes into extracellular space). Total body water distribution occurs only if free water is present.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100% bioavailability. Not administered orally for these purposes; if ingested, dextrose undergoes first-pass metabolism (oral bioavailability ~50-60% due to hepatic extraction) and sodium chloride is fully absorbed.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
Not applicable; contains sodium chloride and dextrose; monitor serum sodium and glucose in renal impairment. For GFR <30 m L/min, use with caution due to risk of hypernatremia and fluid overload.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific dose adjustment; monitor blood glucose in hepatic impairment due to risk of hyperglycemia.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Intravenous infusion; dose based on fluid and electrolyte needs, typically 5-10 m L/kg per hour, adjusted for clinical response; maximum rate 20 m L/kg/h in neonates.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Use with caution; lower infusion rates recommended due to reduced renal function and higher risk of fluid overload and electrolyte disturbances; monitor serum sodium and glucose closely.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
No FDA black box warnings.
None
Hyperglycemia in patients with diabetes or stress-induced hyperglycemia,Fluid overload in patients with heart failure, renal impairment, or edematous states,Hyponatremia (especially in children, elderly, and post-operative patients),Hypernatremia with excessive administration,Osmotic demyelination syndrome with rapid correction of hyponatremia,Phlebitis or extravasation at infusion site
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hyperglycemia (severe) when dextrose use is inadvisable,Hypernatremia,Acute intracranial hemorrhage (if using hypotonic solutions, but not applicable here),Severe renal impairment (oliguria/anuria) with volume overload risk,Patients with known hypersensitivity to dextrose or corn-based products
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No direct food interactions. However, monitor total sodium and glucose intake if patient is on a restricted diet for diabetes or hypertension.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Dextrose and sodium chloride are physiologic substances. No teratogenic risk at standard doses. Excessive sodium may cause maternal hypernatremia with fetal effects indirectly. No trimester-specific risks.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Exogenous dextrose and sodium chloride are normal blood constituents; negligible transfer into milk. M/P ratio not applicable. Compatible with breastfeeding.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No specific dose adjustments for dextrose 5% and sodium chloride 0.9%; use standard dosing. Monitor for gestational hyperglycemia and edema; adjust rate based on clinical status.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Must confirm IV access patency before infusion; hypertonic 0.9% Na Cl may cause phlebitis. Use with caution in heart failure, renal impairment, or hypernatremia. Monitor serum glucose and sodium levels during prolonged administration. Not suitable for dilution of incompatible medications.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Inform your doctor if you have heart disease, kidney problems, or high blood pressure.,Report any signs of allergic reaction (rash, itching, swelling) or infusion site pain/redness.,This solution provides sugar and salt; your fluid and electrolyte levels will be monitored.,Do not stop or adjust the infusion rate without medical advice.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% is a Electrolyte that works by Dextrose 5% provides a source of calories and fluid for hydration, preventing ketosis by providing a minimal carbohydrate source. Sodium chloride 0.9% supplies electrolytes and maintains osmotic pressure in extracellular fluid.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.9% is: Intravenous infusion; typical adult dose is 500-1000 m L as a single dose, administered at a rate determined by clinical condition (e.g., 100-200 m L/h for maintenance).. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.9% is classified as Category A/B. Dextrose and sodium chloride are physiologic substances. No teratogenic risk at standard doses. Excessive sodium may cause maternal hypernatremia with fetal effects indirectly. No . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.